In the VALOR-HCM trial, mavacamten reduced the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy.
Speaking at the recent CSANZ 2023 meeting in Adelaide, Professor Srihari Naidu of Westchester Medical Centre, New York, explained the real world impact of the benefits of the selective allosteric and reversible cardiac myosin inhibitor for patients in terms of symptoms and quality of life, as well as favourable cardiac remodelling.